Stef Smith Research Grant
Funds early-career research into the cause, diagnosis, or non-drug management of myasthenia gravis to improve scientific understanding and patient care.
Funder: UCB
Due Dates: February 28, 2026 (Phase 1 submission) | October 31, 2026 (Phase 2 submission)
Funding Amounts: Up to €200,000 total per project (€100,000/year, max 2 years); 1–2 projects funded.
Summary: Supports innovative research on the cause, diagnosis, or management of myasthenia gravis (excluding drug treatments) to advance patient care and scientific understanding.
Key Information: Lead investigator must be ≤5 years post-neurology training and not beyond Assistant Professor.
Description
This grant, offered by UCB, funds innovative research projects focused on the cause, diagnosis, or management of myasthenia gravis, with the explicit exclusion of pharmacological (drug) treatments. The aim is to improve scientific understanding and patient care for myasthenia gravis. The grant particularly supports early-career investigators and healthcare organizations capable of conducting high-impact, scientifically rigorous studies. The program honors Stef Smith, whose resilience with myasthenia gravis inspired ongoing research efforts.
